Loading
GTB-3650 is a protein from GT Biopharma that wakes up natural killer cells and points them at leukaemia cells carrying the CD33 marker. It is in a first trial in people whose leukaemia has come back.
GTB-3650 is GT Biopharma's first second-generation camelid nanobody TriKE. The IND was cleared and enrolment began on 21 January 2025 in a phase 1 dose-escalation study (NCT06594445) in relapsed or refractory CD33-expressing haematological cancers, including refractory acute myeloid leukaemia and high-risk myelodysplastic syndrome, with up to seven cohorts of two patients and dosing in two-week blocks for up to four months.
A single fusion protein of a camelid nanobody against CD16 on natural killer cells, a single-chain variable fragment against CD33 on tumour cells, and wild-type human IL-15 to drive natural killer cell expansion, as described by GT Biopharma. Connects to CD33.
1.One arm of GTB-3650 binds CD33 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"GTB-3650" OR ABSTRACT:"GTB-3650" OR TITLE:"GTB-3650 TriKE" OR ABSTRACT:"GTB-3650 TriKE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GTB-3650, not a curated reading list.
Shares NK cell engagers, GT Biopharma and the tag pipeline.
Shares CD33 and the tag pipeline.
Shares CD33 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/